Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.
Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has not been presented.



We systematically searched research databases, conference abstracts and trial registries for any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS), to inform future trial design.



Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in observational studies. In those with early-stage colorectal cancer, metformin use was associated with a significant benefit in all outcomes [RFS hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.47-0.85; OS HR 0.69, CI 0.58-0.83; CSS HR 0.58, CI 0.39-0.86]. For men with early-stage prostate cancer, metformin was associated with significant, or borderline significant, benefits in all outcomes (RFS HR 0.83, CI 0.69-1.00; OS HR 0.82, CI 0.73-0.93; CSS HR 0.58, CI 0.37-0.93); however, there was significant heterogeneity between studies. The data suggest that prostate cancer patients treated with radical radiotherapy may benefit more from metformin (RFS HR 0.45, CI 0.29-0.70). In breast and urothelial cancer, no significant benefits were identified. Sufficient data were not available to conduct analyses on the impact of metformin dose and duration.



Our findings suggest that metformin could be a useful adjuvant agent, with the greatest benefits seen in colorectal and prostate cancer, particularly in those receiving radical radiotherapy, and randomised, controlled trials which investigate dose and duration, alongside efficacy, are advocated.
MRC Clinical Trials Unit at University College London, London, UK c.coyle@ucl.ac.uk.
C
C
Coyle
MRC Clinical Trials Unit at University College London, London, UK.
F H
FH
Cafferty
MRC Clinical Trials Unit at University College London, London, UK.
C
C
Vale
MRC Clinical Trials Unit at University College London, London, UK.
R E
RE
Langley
D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D006801:Humans; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology
D008687:Metformin
adjuvant; breast cancer; colorectal cancer; metformin; prostate cancer; repurposing
Diabetes Care. 2013 Oct;36(10):3018-26
23633525
Lancet. 2015 Mar 28;385(9974):1206-18
25479696
BMC Med. 2011 Apr 06;9:33
21470407
Lancet. 2010 Nov 20;376(9754):1741-50
20970847
BJU Int. 2013 Dec;112(8):1105-12
24053906
Urol Oncol. 2015 Feb;33(2):67.e15-23
25153774
Acta Diabetol. 2011 Dec;48(4):297-302
21424914
Int J Cancer. 2012 Aug 1;131(3):752-9
21913184
Urol Oncol. 2014 Jan;32(1):43.e1-7
23810664
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1364-73
23753040
BMC Med Res Methodol. 2013 Mar 25;13:50
23530582
Ann Intern Med. 2013 Jul 16;159(2):77-85
23856681
Cancer Epidemiol. 2013 Jun;37(3):207-18
23352629
Ann Surg. 2016 Jan;263(1):96-102
25575260
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Lancet Oncol. 2016 Apr;17(4):475-483
26947328
Am J Surg. 2010 Jul;200(1):59-63
20074697
Oncologist. 2013;18(12):1248-55
24258613
Cancer Med. 2014 Aug;3(4):1025-34
24944108
Cancer Causes Control. 2016 Jan;27(1):105-13
26537119
Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
20947488
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1974-84
25030683
Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7
24100644
PLoS One. 2012;7(3):e33411
22448244
Breast Cancer Res Treat. 2012 Oct;135(3):639-46
22847511
Prostate Cancer Prostatic Dis. 2015 Mar;18(1):63-8
25403419
Diabetes Obes Metab. 2014 Aug;16(8):707-10
24460896
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005552
17253562
Trials. 2007 Jun 07;8:16
17555582
Oncologist. 2015 May;20(5):546-53
25802404
Circulation. 2009 Oct 20;120(16):1640-5
19805654
Gynecol Oncol. 2014 Feb;132(2):438-42
24269517
PLoS One. 2014 Dec 29;9(12):e116327
25545701
PLoS One. 2014 Mar 19;9(3):e91818
24647047
Radiother Oncol. 2011 Jun;99(3):293-9
21715037
Cancer. 2012 Mar 1;118(5):1202-11
21800293
Stat Med. 2002 Nov 30;21(22):3337-51
12407676
PLoS One. 2014 Jul 28;9(7):e102670
25068257
Diabetes Care. 2010 Jun;33(6):1304-8
20299480
Clin Cancer Res. 2013 Dec 15;19(24):6741-50
24141625
Int Urol Nephrol. 2013 Feb;45(1):121-7
23054323
PLoS One. 2015 Mar 20;10(3):e0117344
25794005
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E687-91
24282458
J Mol Endocrinol. 2012 Mar 29;48(3):R31-43
22355097
Am J Clin Nutr. 2007 Sep;86(3):s836-42
18265477
Eur J Surg Oncol. 2014 Jan;40(1):113-20
24113620
World J Urol. 2014 Aug;32(4):999-1005
24062093
Oncologist. 2016 Dec;21(12):1509-1521
27881709
Br J Cancer. 2015 Jul 28;113(3):403-10
26180924
Urol Oncol. 2014 Jan;32(1):49.e7-14
24140245
Cancer Res. 2007 Nov 15;67(22):10804-12
18006825
J Clin Oncol. 2013 Sep 1;31(25):3069-75
23918942
PLoS One. 2013;8(2):e55196
23405123
J Contemp Brachytherapy. 2014 Oct;6(3):254-61
25337126
Eur Urol. 2013 Apr;63(4):709-16
23287698
Cancer Prev Res (Phila). 2014 Sep;7(9):867-85
24985407
Lancet. 2015 Oct 3;386(10001):1353-1361
26211824
Ann Oncol. 2013 Jun;24(6):1427-34
23508824
Cancer Prev Res (Phila). 2010 Sep;3(9):1077-83
20810669
Breast Cancer Res Treat. 2012 Oct;135(3):821-30
22933030
Prostate Cancer Prostatic Dis. 2015 Jun;18(2):110-21
25667109
Oncologist. 2015 Nov;20(11):1236-44
26446233
Br J Cancer. 2011 Oct 11;105(8):1107-13
21847126
Lancet. 2011 Dec 17;378(9809):2081-7
22036019
J Clin Invest. 2013 Jul;123(7):2764-72
23863634
Stat Med. 1998 Dec 30;17(24):2815-34
9921604
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):36-41
26520788
Diabetes Care. 2012 Dec;35(12):2665-73
23173135
Breast Cancer Res Treat. 2011 Aug;128(3):783-94
21655990
Oncologist. 2012;17(6):813-22
22643536